Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of selective small-molecule mRNA drugs and their mechanisms of action. The company combines high-scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using artificial intelligence to elucidate the mechanism of action of active molecules. This level of automation of phenotypic screening of mRNA modulators together with its AI-driven MOA elucidation has enabled Anima Biotech to develop a broad pipeline across 18 different discovery programs in various therapeutic areas. Anima's wholly owned pipeline programs are in fibrosis (collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), oncology (c-Myc mRNA biology modulators and mutation-agnostic mKras mRNA biology modulators), and neuroscience (Tau; Alzheimer's disease and pain; Nav1.7 mRNA biology modulators). In addition, Anima established strategic collaborations with the pharmaceutical industry in partnered programs including Lilly, Takeda Pharmaceuticals, and Abbvie.